|
Oct 24
|
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
|
|
Sep 4
|
Recent uptick might appease Sangamo Therapeutics, Inc. (NASDAQ:SGMO) institutional owners after losing 82% over the past year
|
|
Jul 20
|
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
|
|
Jul 19
|
The past five years for Sangamo Therapeutics (NASDAQ:SGMO) investors has not been profitable
|
|
Jul 17
|
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
|